Sign inJoin waitlistJoin the waitlist

JL

Jason Luke

Hematology & Oncology

Credentials: · · · ·

History

UPMC Medical Education
2009–2012
Internal Medicine
Boston University Medical Center
2006–2009
Doctor of Medicine
2002–2006

Research

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Science · 2018 · 2,467 citations
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Nature Reviews Clinical Oncology · 2017 · First of 4 authors · 980 citations
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
The Lancet · 2024 · 686 citations

Stephen Hodi
21 papers
Thomas Gajewski
21 papers
Diwakar Davar
20 papers
John Kirkwood
20 papers
Patrick Ott
18 papers
Steven Chmura
16 papers
Ryan Augustin
14 papers · 14 as a resident
RC
Richard Carvajal
11 papers
YN
Yana Najjar
11 papers
HZ
Hassane Zarour
10 papers
Michael Postow
10 papers · 2 as a fellow
Omid Hamid
10 papers

Grants

Immune Exclusion in Cancer Immunotherapy
National Institute of Dental and Craniofacial Research · R01
PI · $1.8M · University of Pittsburgh at Pittsburgh
2022–2027
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $989.7K · University of Pittsburgh at Pittsburgh
1997–2027
NCI ETCTN Pittsburgh Cancer Consortium (PCC)
National Cancer Institute · UM1
PI · $2.2M · University of Pittsburgh at Pittsburgh
2014–2026

Clinical trials

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Principal investigator · Recruiting · Phase 1
Kiromic BioPharma Inc.
2023–2026
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Principal investigator · Completed · Phase 2
Jason J. Luke, MD
2021–2023
Fear of Recurrence and Stopping Immunotherapy
Principal investigator · Recruiting
University of Pittsburgh
2021–2028
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
Principal investigator · Terminated · Phase 1, Phase 2
Jason J. Luke, MD
2021–2022